Cover Image
市場調查報告書

MultiCell Technologies, Inc. - 產品平台檢討

MultiCell Technologies, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226269
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
MultiCell Technologies, Inc. - 產品平台檢討 MultiCell Technologies, Inc. - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 32 Pages
簡介

MultiCell Technologies, Inc.是總公司設於美國的生物製藥企業,原名為Exten Industries, Inc.。專門開發針對神經性疾病,肝疾病,癌症,介入心臟病學末稍血管的新治療藥及藥物研發工具。

本報告提供MultiCell Technologies, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

MultiCell Technologies, Inc.的基本資料

  • MultiCell Technologies, Inc.概要
  • 主要資訊
  • 企業資料

MultiCell Technologies, Inc.:R&D概要

  • 主要的治療範圍

MultiCell Technologies, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

MultiCell Technologies, Inc.:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

MultiCell Technologies, Inc.:藥物簡介

  • (lofepramine + phenylalanine)
  • MCT-465
  • MCT-485
  • MCT-475

MultiCell Technologies, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

MultiCell Technologies, Inc.:最新的開發平台資訊

MultiCell Technologies, Inc.:開發暫停中的計劃

MultiCell Technologies, Inc.:企業理念

MultiCell Technologies, Inc.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07028CDB

Summary

Global Markets Direct's, 'MultiCell Technologies, Inc. - Product Pipeline Review - 2015', provides an overview of the MultiCell Technologies, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MultiCell Technologies, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of MultiCell Technologies, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of MultiCell Technologies, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the MultiCell Technologies, Inc.'s pipeline products

Reasons to buy

  • Evaluate MultiCell Technologies, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of MultiCell Technologies, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the MultiCell Technologies, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of MultiCell Technologies, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of MultiCell Technologies, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of MultiCell Technologies, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • MultiCell Technologies, Inc. Snapshot
    • MultiCell Technologies, Inc. Overview
    • Key Information
    • Key Facts
  • MultiCell Technologies, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • MultiCell Technologies, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • MultiCell Technologies, Inc. - Pipeline Products Glance
    • MultiCell Technologies, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • MultiCell Technologies, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • MultiCell Technologies, Inc. - Drug Profiles
    • (lofepramine hydrochloride + phenylalanine)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MCT-465
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MCT-485
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MCT-475
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • MultiCell Technologies, Inc. - Pipeline Analysis
    • MultiCell Technologies, Inc. - Pipeline Products by Target
    • MultiCell Technologies, Inc. - Pipeline Products by Route of Administration
    • MultiCell Technologies, Inc. - Pipeline Products by Molecule Type
    • MultiCell Technologies, Inc. - Pipeline Products by Mechanism of Action
  • MultiCell Technologies, Inc. - Recent Pipeline Updates
  • MultiCell Technologies, Inc. - Dormant Projects
  • MultiCell Technologies, Inc. - Company Statement
  • MultiCell Technologies, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • MultiCell Technologies, Inc., Key Information
  • MultiCell Technologies, Inc., Key Facts
  • MultiCell Technologies, Inc. - Pipeline by Indication, 2015
  • MultiCell Technologies, Inc. - Pipeline by Stage of Development, 2015
  • MultiCell Technologies, Inc. - Monotherapy Products in Pipeline, 2015
  • MultiCell Technologies, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • MultiCell Technologies, Inc. - Partnered Products in Pipeline, 2015
  • MultiCell Technologies, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • MultiCell Technologies, Inc. - Phase II, 2015
  • MultiCell Technologies, Inc. - Preclinical, 2015
  • MultiCell Technologies, Inc. - Discovery, 2015
  • MultiCell Technologies, Inc. - Pipeline by Target, 2015
  • MultiCell Technologies, Inc. - Pipeline by Route of Administration, 2015
  • MultiCell Technologies, Inc. - Pipeline by Molecule Type, 2015
  • MultiCell Technologies, Inc. - Pipeline Products by Mechanism of Action, 2015
  • MultiCell Technologies, Inc. - Recent Pipeline Updates, 2015
  • MultiCell Technologies, Inc. - Dormant Developmental Projects,2015
  • MultiCell Technologies, Inc., Subsidiaries

List of Figures

  • MultiCell Technologies, Inc. - Pipeline by Top 10 Indication, 2015
  • MultiCell Technologies, Inc. - Pipeline by Stage of Development, 2015
  • MultiCell Technologies, Inc. - Monotherapy Products in Pipeline, 2015
  • MultiCell Technologies, Inc. - Pipeline by Top 10 Target, 2015
  • MultiCell Technologies, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • MultiCell Technologies, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top